XML 16 R5.htm IDEA: XBRL DOCUMENT
v3.20.2

CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) | Total | Preferred Stock | Preferred Stock Series D Convertible Preferred Stock | Preferred Stock Series C Convertible Preferred Stock | Common Stock | Common Stock Series D Convertible Preferred Stock | Common Stock Series C Convertible Preferred Stock | Additional Paid-In Capital | Additional Paid-In Capital Series D Convertible Preferred Stock | Additional Paid-In Capital Series E Convertible Preferred Stock | Additional Paid-In Capital Series C Convertible Preferred Stock | Service Receivable | Accumulated Deficit | Accumulated Deficit Series D Convertible Preferred Stock | Accumulated Deficit Series E Convertible Preferred Stock
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Balance, beginning (in shares) at Dec. 31, 2018 |  |  | 60,600 |  |  | 3,831,879 |  |  |  |  |  |  |  |  |  |
Balance, beginning at Dec. 31, 2018 |  | $ 10,084,192 | $ 60 |  |  | $ 7,742 |  |  | $ 202,267,605 |  |  |  | $ 0 | $ (192,191,215) |  |
Increase (Decrease) in Stockholders' Equity [Roll Forward] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation |  | 200,067 |  |  |  |  |  |  | 200,067 |  |  |  |  |  |  |
Issuance of common stock upon exercise of warrants (in shares) |  |  |  |  |  | 497,313 |  |  |  |  |  |  |  |  |  |
Issuance of common stock upon exercise of warrants |  | 3,282,266 |  |  |  | $ 50 |  |  | 3,282,216 |  |  |  |  |  |  |
Issuance of common stock upon vesting of restricted stock units (in shares) |  |  |  |  |  | 6,362 |  |  |  |  |  |  |  |  |  |
Issuance of common stock upon vesting of restricted stock units |  |  |  |  |  | $ 4 |  |  | (4) |  |  |  |  |  |  |
Preferred stock dividend payable on Series A Convertible Preferred Stock |  | (6,060) |  |  |  |  |  |  |  |  |  |  |  | (6,060) |  |
Release of clinical trial funding commitment |  | 70,487 |  |  |  |  |  |  |  |  |  |  | 70,487 |  |  |
Net loss |  | (3,904,771) |  |  |  |  |  |  |  |  |  |  |  | (3,904,771) |  |
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares) |  |  | 200,000 |  |  | 183,334 |  |  |  |  |  |  |  |  |  |
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment |  | (40,000) | $ 200 |  |  | $ 110 |  |  | 1,634,690 |  |  |  | (1,675,000) |  |  |
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance |  |  |  |  |  |  |  |  | 268,269 |  |  |  |  | (268,269) |  |
Issuance of common stock for share rounding as a result of reverse stock split (in shares) |  |  |  |  |  | 6,466 |  |  |  |  |  |  |  |  |  |
Balance, ending (in shares) at Mar. 31, 2019 |  |  | 260,600 |  |  | 4,525,354 |  |  |  |  |  |  |  |  |  |
Balance, ending at Mar. 31, 2019 |  | 9,686,181 | $ 260 |  |  | $ 7,906 |  |  | 207,652,843 |  |  |  | (1,604,513) | (196,370,315) |  |
Balance, beginning (in shares) at Dec. 31, 2018 |  |  | 60,600 |  |  | 3,831,879 |  |  |  |  |  |  |  |  |  |
Balance, beginning at Dec. 31, 2018 |  | 10,084,192 | $ 60 |  |  | $ 7,742 |  |  | 202,267,605 |  |  |  | 0 | (192,191,215) |  |
Increase (Decrease) in Stockholders' Equity [Roll Forward] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | (12,171,623) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Balance, ending (in shares) at Sep. 30, 2019 |  |  | 60,600 |  |  | 6,436,505 |  |  |  |  |  |  |  |  |  |
Balance, ending at Sep. 30, 2019 |  | 6,655,980 | $ 60 |  |  | $ 8,096 |  |  | 212,463,077 |  |  |  | (1,165,966) | (204,649,287) |  |
Balance, beginning (in shares) at Mar. 31, 2019 |  |  | 260,600 |  |  | 4,525,354 |  |  |  |  |  |  |  |  |  |
Balance, beginning at Mar. 31, 2019 |  | 9,686,181 | $ 260 |  |  | $ 7,906 |  |  | 207,652,843 |  |  |  | (1,604,513) | (196,370,315) |  |
Increase (Decrease) in Stockholders' Equity [Roll Forward] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation |  | 148,834 |  |  |  |  |  |  | 148,834 |  |  |  |  |  |  |
Sale of common stock and warrants (in shares) |  |  |  |  |  | (421,917) |  |  |  |  |  |  |  |  |  |
Sale of common stock and warrants |  | (2,902,740) |  |  |  | $ (42) |  |  | (2,902,698) |  |  |  |  |  |  |
Issuance of common stock upon exercise of warrants (in shares) |  |  |  |  |  | 156,353 |  |  |  |  |  |  |  |  |  |
Issuance of common stock upon exercise of warrants |  | 1,564 |  |  |  | $ 16 |  |  | 1,548 |  |  |  |  |  |  |
Issuance of common stock upon vesting of restricted stock units (in shares) |  |  |  |  |  | 4,433 |  |  |  |  |  |  |  |  |  |
Preferred stock dividend payable on Series A Convertible Preferred Stock |  | (6,060) |  |  |  |  |  |  |  |  |  |  |  | (6,060) |  |
Release of clinical trial funding commitment |  | 240,279 |  |  |  |  |  |  |  |  |  |  | 240,279 |  |  |
Net loss |  | (4,125,303) |  |  |  |  |  |  |  |  |  |  |  | (4,125,303) |  |
Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares) |  |  |  |  | (200,000) |  |  | 333,333 |  |  |  |  |  |  |  |
Issuance of common stock upon conversion of Series D Convertible Preferred Stock |  |  |  |  | $ (200) |  |  | $ 33 |  |  |  | $ 167 |  |  |  |
Balance, ending (in shares) at Jun. 30, 2019 |  |  | 60,600 |  |  | 5,441,390 |  |  |  |  |  |  |  |  |  |
Balance, ending at Jun. 30, 2019 |  | 8,848,235 | $ 60 |  |  | $ 7,997 |  |  | 210,706,090 |  |  |  | (1,364,234) | (200,501,678) |  |
Increase (Decrease) in Stockholders' Equity [Roll Forward] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation |  | 266,325 |  |  |  |  |  |  | 266,325 |  |  |  |  |  |  |
Sale of common stock and warrants (in shares) |  |  |  |  |  | (271,744) |  |  |  |  |  |  |  |  |  |
Sale of common stock and warrants |  | (1,483,581) |  |  |  | $ (27) |  |  | (1,483,554) |  |  |  |  |  |  |
Issuance of common stock upon exercise of warrants (in shares) |  |  |  |  |  | 717,969 |  |  |  |  |  |  |  |  |  |
Issuance of common stock upon exercise of warrants |  | 7,180 |  |  |  | $ 72 |  |  | 7,108 |  |  |  |  |  |  |
Issuance of common stock upon vesting of restricted stock units (in shares) |  |  |  |  |  | 5,402 |  |  |  |  |  |  |  |  |  |
Preferred stock dividend payable on Series A Convertible Preferred Stock |  | (6,060) |  |  |  |  |  |  |  |  |  |  |  | (6,060) |  |
Release of clinical trial funding commitment |  | 198,268 |  |  |  |  |  |  |  |  |  |  | 198,268 |  |  |
Net loss |  | (4,141,549) |  |  |  |  |  |  |  |  |  |  |  | (4,141,549) |  |
Balance, ending (in shares) at Sep. 30, 2019 |  |  | 60,600 |  |  | 6,436,505 |  |  |  |  |  |  |  |  |  |
Balance, ending at Sep. 30, 2019 |  | 6,655,980 | $ 60 |  |  | $ 8,096 |  |  | 212,463,077 |  |  |  | (1,165,966) | (204,649,287) |  |
Balance, beginning (in shares) at Dec. 31, 2019 |  |  | 60,600 |  |  | 8,593,633 |  |  |  |  |  |  |  |  |  |
Balance, beginning at Dec. 31, 2019 |  | 7,311,344 | $ 60 |  |  | $ 8,312 |  |  | 217,172,528 |  |  |  | (971,673) | (208,897,883) |  |
Increase (Decrease) in Stockholders' Equity [Roll Forward] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation |  | 177,309 |  |  |  |  |  |  | 177,309 |  |  |  |  |  |  |
Sale of common stock and warrants (in shares) |  |  |  |  |  | (800,000) |  |  |  |  |  |  |  |  |  |
Sale of common stock and warrants |  | (1,000,001) |  |  |  | $ (80) |  |  | (999,921) |  |  |  |  |  |  |
Issuance of common stock upon exercise of warrants (in shares) |  |  |  |  |  | 1,610,144 |  |  |  |  |  |  |  |  |  |
Issuance of common stock upon exercise of warrants |  | 1,456,369 |  |  |  | $ 161 |  |  | 1,456,208 |  |  |  |  |  |  |
Issuance of common stock upon vesting of restricted stock units (in shares) |  |  |  |  |  | 6,810 |  |  |  |  |  |  |  |  |  |
Issuance of common stock upon vesting of restricted stock units |  |  |  |  |  | $ 1 |  |  | (1) |  |  |  |  |  |  |
Preferred stock dividend payable on Series A Convertible Preferred Stock |  | (6,060) |  |  |  |  |  |  |  |  |  |  |  | (6,060) |  |
Release of clinical trial funding commitment |  | 293,017 |  |  |  |  |  |  |  |  |  |  | 293,017 |  |  |
Net loss |  | (4,088,562) |  |  |  |  |  |  |  |  |  |  |  | (4,088,562) |  |
Balance, ending (in shares) at Mar. 31, 2020 |  |  | 60,600 |  |  | 11,010,587 |  |  |  |  |  |  |  |  |  |
Balance, ending at Mar. 31, 2020 |  | 6,143,418 | $ 60 |  |  | $ 8,554 |  |  | 219,805,965 |  |  |  | (678,656) | (212,992,505) |  |
Balance, beginning (in shares) at Dec. 31, 2019 |  |  | 60,600 |  |  | 8,593,633 |  |  |  |  |  |  |  |  |  |
Balance, beginning at Dec. 31, 2019 |  | 7,311,344 | $ 60 |  |  | $ 8,312 |  |  | 217,172,528 |  |  |  | (971,673) | (208,897,883) |  |
Increase (Decrease) in Stockholders' Equity [Roll Forward] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | (12,709,625) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Balance, ending (in shares) at Sep. 30, 2020 |  |  | 926,424 |  |  | 26,285,743 |  |  |  |  |  |  |  |  |  |
Balance, ending at Sep. 30, 2020 |  | 33,522,550 | $ 926 |  |  | $ 10,081 |  |  | 260,807,295 |  |  |  | (2,403,580) | (224,892,172) |  |
Balance, beginning (in shares) at Mar. 31, 2020 |  |  | 60,600 |  |  | 11,010,587 |  |  |  |  |  |  |  |  |  |
Balance, beginning at Mar. 31, 2020 |  | 6,143,418 | $ 60 |  |  | $ 8,554 |  |  | 219,805,965 |  |  |  | (678,656) | (212,992,505) |  |
Increase (Decrease) in Stockholders' Equity [Roll Forward] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation |  | 281,776 |  |  |  |  |  |  | 281,776 |  |  |  |  |  |  |
Issuance of common stock upon exercise of warrants (in shares) |  |  |  |  |  | 3,473,393 |  |  |  |  |  |  |  |  |  |
Issuance of common stock upon exercise of warrants |  | 4,605,017 |  |  |  | $ 347 |  |  | 4,604,670 |  |  |  |  |  |  |
Issuance of common stock upon vesting of restricted stock units (in shares) |  |  |  |  |  | 2,250 |  |  |  |  |  |  |  |  |  |
Preferred stock dividend payable on Series A Convertible Preferred Stock |  | (6,060) |  |  |  |  |  |  |  |  |  |  |  | (6,060) |  |
Release of clinical trial funding commitment |  | 213,492 |  |  |  |  |  |  |  |  |  |  | 213,492 |  |  |
Net loss |  | (4,124,532) |  |  |  |  |  |  |  |  |  |  |  | (4,124,532) |  |
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment (in shares) |  |  | 154,670 |  |  | 602,833 |  |  |  |  |  |  |  |  |  |
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment |  | (7,500) | $ 15 |  |  | $ 60 |  |  | 2,292,425 |  |  |  | (2,300,000) |  |  |
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance |  |  |  |  |  |  |  |  |  | $ 601,767 | $ 2,664,717 |  |  |  | $ (601,767) | $ (2,664,717)
Sale of common stock, preferred stock and warrants (in shares) | [1] |  | 865,824 |  |  | 4,689,313 |  |  |  |  |  |  |  |  |  |
Sale of common stock, preferred stock and warrants | [1] | (17,278,428) | $ 866 |  |  | $ 469 |  |  | 17,277,093 |  |  |  |  |  |  |
Issuance of common stock upon conversion of Series D Convertible Preferred Stock (in shares) |  |  |  | (154,670) |  |  | 1,546,700 |  |  |  |  |  |  |  |  |
Issuance of common stock upon conversion of Series D Convertible Preferred Stock |  |  |  | $ (15) |  |  | $ 155 |  |  | $ (140) |  |  |  |  |  |
Balance, ending (in shares) at Jun. 30, 2020 |  |  | 926,424 |  |  | 21,325,076 |  |  |  |  |  |  |  |  |  |
Balance, ending at Jun. 30, 2020 |  | 24,384,039 | $ 926 |  |  | $ 9,585 |  |  | 247,528,273 |  |  |  | (2,765,164) | (220,389,581) |  |
Increase (Decrease) in Stockholders' Equity [Roll Forward] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock-based compensation |  | 361,884 |  |  |  |  |  |  | 361,884 |  |  |  |  |  |  |
Issuance of common stock upon exercise of warrants (in shares) |  |  |  |  |  | 4,956,084 |  |  |  |  |  |  |  |  |  |
Issuance of common stock upon exercise of warrants |  | 12,910,802 |  |  |  | $ 496 |  |  | 12,910,306 |  |  |  |  |  |  |
Issuance of common stock upon vesting of restricted stock units (in shares) |  |  |  |  |  | 1,250 |  |  |  |  |  |  |  |  |  |
Preferred stock dividend payable on Series A Convertible Preferred Stock |  | (6,060) |  |  |  |  |  |  |  |  |  |  |  | (6,060) |  |
Release of clinical trial funding commitment |  | 361,584 |  |  |  |  |  |  |  |  |  |  | 361,584 |  |  |
Net loss |  | (4,496,531) |  |  |  |  |  |  |  |  |  |  |  | (4,496,531) |  |
Issuance of common stock upon exercise of stock options (in shares) |  |  |  |  |  | 3,333 |  |  |  |  |  |  |  |  |  |
Issuance of common stock upon exercise of stock options |  | 6,832 |  |  |  |  |  |  | 6,832 |  |  |  |  |  |  |
Balance, ending (in shares) at Sep. 30, 2020 |  |  | 926,424 |  |  | 26,285,743 |  |  |  |  |  |  |  |  |  |
Balance, ending at Sep. 30, 2020 |  | $ 33,522,550 | $ 926 |  |  | $ 10,081 |  |  | $ 260,807,295 |  |  |  | $ (2,403,580) | $ (224,892,172) |  |
[1] | Net of expenses of $616,143, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $370,666.

X
- Definition Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock + References No definition available. + Details
Name: | crdf_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
Namespace Prefix: | crdf_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Release Of Clinical Trial Funding Commitment + References No definition available. + Details
Name: | crdf_ReleaseOfClinicalTrialFundingCommitment
Namespace Prefix: | crdf_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sale Of Stock, Common And Warrants, Net, Shares + References No definition available. + Details
Name: | crdf_SaleOfStockCommonAndWarrantsNetShares
Namespace Prefix: | crdf_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sale Of Stock, Value, Common And Warrants, Net + References No definition available. + Details
Name: | crdf_SaleOfStockValueCommonAndWarrantsNet
Namespace Prefix: | crdf_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Stock Issued During Period Restricted Stock Units Released + References No definition available. + Details
Name: | crdf_StockIssuedDuringPeriodRestrictedStockUnitsReleased
Namespace Prefix: | crdf_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of shares issued during the period upon cash exercise of warrants. + References No definition available. + Details
Name: | crdf_StockIssuedDuringPeriodSharesWarrantsExercised
Namespace Prefix: | crdf_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Stock Issued During Period, Value, Restricted Stock Units Releases + References No definition available. + Details
Name: | crdf_StockIssuedDuringPeriodValueRestrictedStockUnitsReleases
Namespace Prefix: | crdf_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The equity impact during the period due to the cash exercise of warrants. + References No definition available. + Details
Name: | crdf_StockIssuedDuringPeriodValueWarrantsExercised
Namespace Prefix: | crdf_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899 + Details
Name: | us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 405 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817 + Details
Name: | us-gaap_DividendsPreferredStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + References No definition available. + Details
Name: | us-gaap_IncreaseDecreaseInStockholdersEquityRollForward
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227 Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details
Name: | us-gaap_SharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares issued during the period as a result of the conversion of convertible securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of stock issued attributable to transactions classified as other. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesOther
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of share options (or share units) exercised during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued during the period as a result of a stock split. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesStockSplits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The gross value of stock issued during the period upon the conversion of convertible securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of shares of stock issued attributable to transactions classified as other. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodValueOther
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of stock issued as a result of the exercise of stock options. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612 Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_StockholdersEquity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant